adaptimmune.com (ADAP) Cash Funds per Single Share

Symbol and logo of brand Adaptimmune Therapeutics (ADAP)

The approval of Tecelra has established Adaptimmune (ADAP) as a pioneer in cellular engineering. The development of the TCR ecosystem offers hope to patients with advanced tumors, while the implementation of laboratory robotics optimizes test validation. The cash per share in the daily price action on the GURU.Markets chart demonstrates liquidity, where the 0.00 level reflects the status of the company's financial stability parameter.

ADAP adaptimmune.com: Cash per Single Share in the range 07/04/2022 - 11/15/2025

Comprehensive metric breakdowns and analytics for adaptimmune.com (ADAP)

- market price and analyst price targets:
- cash and cash flow data:
Summary company analysis:ADAP (Adaptimmune Therapeutics plc)
Finished products of Adaptimmune

This indicator determines the liquidity level available to each security holder. By analyzing the cash per share valuation, an investor tracks the issuer's capital dynamics. The metric is calculated by dividing the total cash and cash equivalents by the total number of shares. For Adaptimmune (ADAP), this figure confirms financial stability. The commercial success of T-cell therapy and partnership payments ensure a stable free cash flow.